The Times of London
The Times of London, Wall Street Journal, Fox News, Harper Collins, New York Post, and News Corp (Worldwide media conglomerate) are all owned by Rupert Murdoch. They also control 59% of the news media in Australia.
James Murdoch; (Rupert Murdochs son) sat as a director of GlaxoSmithKline from 2009-2012. GSK was criminally charged in 2010 and given a $3 billion dollar fine for off-label marketing of their drugs. Ironically during this time he was a member of GSK’s Corporate Responsibility Committee.
GSK launched their Malaria vaccine in Africa, April 23, 2019.
James Murdoch is currently the Deputy Chief Operating Officer; Chairman and CEO, International of News Corp. James and Rupert Murdoch have deep financial interests in the pharmaceutical industry.
www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-board-changes/
www.reuters.com/article/us-glaxosmithkline/james-murdoch-to-quit-gsk-board-idUSTRE80Q0OJ20120127
GlaxoSmithKlines Malaria vaccine, its efficacy is 4 out of 10, it must be given in 4 separate doses.
www.the-scientist.com/news-opinion/distribution-of-worlds-first-malaria-vaccine-begins-65777
The Guardian-Media and newspaper
The Guardian has a philanthropic foundation funded arm which receives grants to be focused on particular issues. One donor is Bill and Melinda Gates noted for their promotion of vaccines.
See Foundation Funding
en.wikipedia.org/wiki/The_Guardian
Bill Gates funding GlaxoSmithKline and their Malaria vaccine, CDC paragraph 4 and 5
www.cdc.gov/malaria/features/vaccines.html
Bill Gates owns a substantial amount of shares in 9 large pharmaceutical companies.
www.wsj.com/articles/SB1021577629748680000
Gates founded "Gavi-The Vaccine Alliance". They purchase vaccines from the 9 pharmaceutical corporations he owns these shares in.
They seek donations from governments and organizations.
Donations to "Gavi": US Government $ 1 billion US, Canadian Government $ 1 billion CAD, UK Government $ 1.62 billion USD
The many other donors to "Gavi-The Vaccine Alliance"
www.gavi.org/investing-gavi/funding/donor-profiles
From the New England Journal of medicine the GlaxoSmithKline results show that it is not much of a vaccine, read the efficacy at the bottom paragraph. Efficacy is at 35.9% after the first year, then drops to 2.5% after 4 years.
"In conclusion, RTS,S/AS01 vaccination showed evidence of 35.9% efficacy in the first year after vaccination, but efficacy fell to 2.5% in the fourth year. The cohort with a high exposure index had a partial rebound in clinical malaria cases during the fifth year. This result eroded the benefits that were seen in early years, such that over a period of 7 years, vaccine efficacy was estimated at 4.4%, a rate that was substantially lower than that seen over short-term follow up."
www.nejm.org/doi/full/10.1056/NEJMoa1515257
Of course corporate media will have a problem with a proven malaria cure with 100% efficacy.
